Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Adjuvant checkpoint blockade in high-risk urothelial and kidney cancer

Thomas Powles • 18 Sep 2021
ESMO 2021
Bladder Cancer Kidney Cancer Urothelial Carcinoma Antibodies Atezolizumab Nivolumab Pembrolizumab
KEYNOTE-564

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, gives an overview of the use of adjuvant immune checkpoint blockade in high-risk urothelial and kidney cancer, discussed at the European Society for Medical Oncology (ESMO) 2021 congress. Dr Powles outlines the controversy surrounding this topic, and highlights the importance of clinical trial data and more specifically, overall survival. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

More from Thomas Powles

VOLGA: perioperative durvalumab and neoadjuvant enfortumab vedotin in MIBC
2:04
VOLGA: perioperative durvalumab and neoadjuvant enfortumab vedotin in MIBC
Thomas Powles • 24 Oct 2026
LITESPARK-005: HRQoL with belzutifan versus everolimus for advanced RCC
6:12
LITESPARK-005: HRQoL with belzutifan versus everolimus for advanced RCC
Brian Rini et al. • 31 Mar 2025
Key takeaways from ASCO 2024: advances in kidney cancer biomarkers and neoadjuvant therapy
1:00
Key takeaways from ASCO 2024: advances in kidney cancer biomarkers and neoadjuvant therapy
Thomas Powles • 1 Aug 2024
Exploring ctDNA in muscle-invasive bladder cancer: future applications and current limitations
1:17
Exploring ctDNA in muscle-invasive bladder cancer: future applications and current limitations
Thomas Powles • 1 Jun 2024

Related Videos

KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026
Therapeutic strategies to induce adaptive NK cells and improve outcomes in NMIBC
1:29
Therapeutic strategies to induce adaptive NK cells and improve outcomes in NMIBC
Bérengère Salomé • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals